Thursday, Sep 4, 1997

Health Care Pioneers Reinforce Commitment to Improving Public Health

Kaiser Permanente and Genentech Partner to Measure Outcomes in Stroke Treatment

South San Francisco, Calif. -- September 4, 1997 --

Kaiser Permanente and Genentech, Inc. (NYSE:GNE) today announced a study aimed at assessing the impact of improved patient management on clinical outcomes for victims of stroke, the third cause of death and the leading cause of adult disability in the United States. Designed to monitor and improve the quality, as well as reduce the costs, of stroke care, the study will be implemented at four Kaiser Permanente facilities throughout Northern California.

The agreement builds on Kaiser Permanente and Genentech's existing relationship, which has historically focused on addressing critical public health problems and improving patient care.

Kaiser Permanente plans to conduct a two-year study designed to observe the effect that stroke guidelines and protocols have on the outcomes of stroke patients. The study will include the development of multi-disciplinary stroke teams, the identification of patients at high-risk for stroke, education targeted at both professional and patient audiences as well as the development of study measurement tools to assess patient outcomes.

"We expect this program will serve as a model for improving the way we treat stroke," said David M. Lawrence, MD, chairman and CEO of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals. "This effort is possible only in a truly integrated health care organization that can coordinate a broad spectrum of care."

"This collaboration not only enhances our relationship with a true pioneer in the health care industry, but it provides a gratifying opportunity to apply our considerable resources toward a common public good," said Arthur D. Levinson, Ph.D., president and chief executive officer of Genentech.

There is a new atmosphere surrounding stroke. Traditionally, stroke has been managed as a condition calling for rehabilitation rather than therapeutic intervention on an emergency basis. New developments in the treatment of acute stroke and the availability of a new therapy have led to significant changes in the way stroke is managed at Kaiser Permanente and by other health care providers nationwide.

"It's now possible and critical to manage all aspects of stroke," said Jerry Schlegel, MD, director of the stroke guideline project for The Permanente Medical Group. "In addition to acute stroke treatment, we need to identify at-risk patients and determine the most appropriate means of preventing stroke. We also need to improve rehabilitation for stroke patients, aimed at returning them to active lifestyles. This study will help evaluate our efforts in all three of these areas."

"We hope to apply the knowledge gleaned from this study to other Kaiser Permanente facilities throughout the country, enabling us to provide the best possible care to stroke patients," said William Likosky, MD, director of utilization for The Permanente Medical Group.

The California Division of Kaiser Permanente is a prepaid, health maintenance organization (HMO) serving more than 5 million members throughout the state. The Division has approximately 6,400 physicians and 55,000 employees. It is organized into 12 local market areas which are served by 26 major medical centers.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. Eleven of the currently marketed biotechnology products stem from Genentech science, six of which Genentech markets directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange and Pacific Exchange under the symbol GNE.

# # #